About Mitochondrial glutathione transporter SLC25A40
Mitochondrial glutathione transporter SLC25A40 (SLC25A40) is a protein
from Homo sapiens identified by UniProt accession
Q8TBP6, 338 residues long.
MolForge cross-references it against 0 known binders and
21 disease associations.
Target properties
| Protein name | Mitochondrial glutathione transporter SLC25A40 |
|---|
| UniProt accession | Q8TBP6 |
|---|
| Gene | SLC25A40 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 338 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (21)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.37
- leukocyte count · score 0.15
- myeloid white cell count · score 0.10
- cognitive decline measurement · score 0.07
- neutrophil count · score 0.04
- neoplasm · score 0.01
- Sepsis · score 0.01
- Hypertriglyceridemia · score 0.01
- chronic kidney disease · score 0.01
- ovarian serous adenocarcinoma · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8TBP6-F1 | alphafold | PREDICTED | 78.38 | — |
Amino-acid sequence (338 residues)
MDPETRGQEI IKVTPLQQML ASCTGAILTS VIVTPLDVVK IRLQAQNNPL PKGKCFVYSN GLMDHLCVCE EGGNKLWYKK PGNFQGTLDA FFKIIRNEGI KSLWSGLPPT LVMAVPATVI YFTCYDQLSA LLRSKLGENE TCIPIVAGIV ARFGAVTVIS PLELIRTKMQ SKKFSYVELH RFVSKKVSED GWISLWRGWA PTVLRDVPFS AMYWYNYEIL KKWLCEKSGL YEPTFMINFT SGALSGSFAA VATLPFDVVK TQKQTQLWTY ESHKISMPLH MSTWIIMKNI VAKNGFSGLF SGLIPRLIKI APACAIMIST YEFGKAFFQK QNVRRQQY
Explore Mitochondrial glutathione transporter SLC25A40 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets